$1.52
7.45% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US19188J3005
Symbol
COCP
Sector
Industry

Cocrystal Pharma Inc Stock price

$1.52
+0.18 13.45% 1M
-0.55 26.46% 6M
-0.51 25.00% YTD
-0.39 20.26% 1Y
-3.05 66.78% 3Y
-9.42 86.15% 5Y
-423.29 99.64% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.11 7.45%
ISIN
US19188J3005
Symbol
COCP
Sector
Industry

Key metrics

Market capitalization $15.41m
Enterprise Value $10.14m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.11
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-16.06m
Free Cash Flow (TTM) Free Cash Flow $-13.47m
Cash position $7.00m
EPS (TTM) EPS $-1.56
P/E forward negative
Short interest 0.01%
Show more

Is Cocrystal Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Cocrystal Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Cocrystal Pharma Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Cocrystal Pharma Inc:

Buy
100%

Financial data from Cocrystal Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.12 0.12
50% 50%
-
-0.12 -0.12
-
-
- Selling and Administrative Expenses 4.88 4.88
15% 15%
-
- Research and Development Expense 11 11
23% 23%
-
-16 -16
26% 26%
-
- Depreciation and Amortization 0.12 0.12
-
-
EBIT (Operating Income) EBIT -16 -16
21% 21%
-
Net Profit -16 -16
5% 5%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cocrystal Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cocrystal Pharma Inc Stock News

Neutral
GlobeNewsWire
6 days ago
In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants BOTHELL, Wash., May 15, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three months ended March 31, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business ac...
Neutral
GlobeNewsWire
27 days ago
BOTHELL, Wash., April 24, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its investigative drug candidate CDI-988 was shown to bind to the highly conserved region of the GII.17 protease with excellent potency, similar to that shown across a range of GII.4 norovirus variants that had been the dominant worldwide strains until this year...
Neutral
GlobeNewsWire
about one month ago
BOTHELL, Wash., April 16, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, President and co-CEO, will present a Company overview at the Life Science Innovation Northwest (LSINW) 2025 Conference on Wednesday, April 23, 2025 at 3:00 p.m.
More Cocrystal Pharma Inc News

Company Profile

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded on January 2, 2014 and is headquartered in Bothell, WA.

Head office United States
CEO Sam Lee
Employees 11
Founded 2008
Website www.cocrystalpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today